To assess the pharmacokinetics, safety and tolerability of Abediterol administered once daily for 9 Days, in patients with asthma on Inhaled corticosteroids

Study identifier:D6540C00006

ClinicalTrials.gov identifier:NCT03273127

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1, Randomized, Single-Blind, Placebo Controlled Study to Assess Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients with Asthma on Inhaled Corticosteroids

Medical condition

asthma

Phase

Phase 1

Healthy volunteers

No

Study drug

Abediterol, Placebo

Sex

All

Actual Enrollment

12

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 21 Sept 2017
Primary Completion Date: 09 Nov 2017
Study Completion Date: 09 Nov 2017

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2018 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria